E C Borden
Overview
Explore the profile of E C Borden including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
220
Citations
3563
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Lindner D, Borden E
J Interferon Cytokine Res
. 1997 Dec;
17(11):681-93.
PMID: 9402106
Solid tumors are relatively resistant to growth inhibition by interferons (IFNs). To enhance sensitivity, we assessed combinations of IFNs with tamoxifen in estrogen receptor-positive (ER-positive) and ER-negative human tumor xenografts....
22.
Mackowiak P, Bartlett J, Borden E, Goldblum S, Hasday J, MUNFORD R, et al.
Clin Infect Dis
. 1997 Jul;
25(1):119-38.
PMID: 9243046
Fever has been a preoccupation of clinicians since medicine's beginning. One might therefore expect that basic concepts relating to this physiological response would be well delineated and that such concepts...
23.
Lindner D, Borden E, Kalvakolanu D
Clin Cancer Res
. 1997 Jun;
3(6):931-7.
PMID: 9815768
Solid tumors are relatively resistant to growth inhibition by IFNs. To enhance sensitivity, we assessed combinations of IFNs with all-trans-retinoic acid (RA). Antiproliferative studies in vitro suggested that the growth...
24.
Lindner D, Kalvakolanu D, Borden E
Semin Oncol
. 1997 Jun;
24(3 Suppl 9):S9-99-S9-104.
PMID: 9208879
Alpha-interferons (IFN-alphas) have been shown to be effective agents in inducing the regression of various malignancies, including leukemias and lymphomas as well as solid tumors, and are the first human...
25.
Lindner D, Borden E
Int J Cancer
. 1997 May;
71(3):456-61.
PMID: 9139884
Inhibition of angiogenesis by anti-tumor agents may play a role in tumor growth arrest. Tamoxifen and interferon-alpha/beta (IFN-alpha/beta) exhibit potentiated anti-proliferative activity against tumor cells. However, additional host-mediated effects such...
26.
Galazka A, Revel M, Biffoni M, Borden E
Cytokines Cell Mol Ther
. 1997 Mar;
3(1):27-32.
PMID: 9287241
Patients receiving recombinant human interferon-beta 1a (IFN-beta 1a) produced in Chinese hamster ovary (CHO) cells were tested for the formation of neutralizing antibodies (NABs) to IFN-beta. Samples were tested in...
27.
Kirkwood J, Bryant J, Schiller J, Oken M, Borden E, Whiteside T
J Immunother
. 1997 Mar;
20(2):146-57.
PMID: 9087387
Interferon-gamma (IFN-gamma) has the most potent immunomodulatory activity of all the interferons. This phase II-B study was performed to define time- and dose-dependent immunomodulatory effects mediated by IFN-gamma in a...
28.
Lindner D, Kolla V, Kalvakolanu D, Borden E
Mol Cell Biochem
. 1997 Feb;
167(1-2):169-77.
PMID: 9059994
The molecular basis for the enhanced growth inhibition of MCF-7 human breast cancer xenografts by a combination of human interferon-beta (IFN-beta) and tamoxifen was investigated. Treatment of MCF-7, MDA-MB-231, and...
29.
Taylor J, DCunha J, Tom P, OBrien W, Borden E
J Interferon Cytokine Res
. 1996 Nov;
16(11):937-40.
PMID: 8938569
ISG-15, a 15-kDa protein encoded by an interferon (IFN)-stimulated gene (ISG), was produced in human corneal cell cultures prepared from donor corneas in response to each of three major types...
30.
Byhardt R, Vaickus L, Witt P, Chang A, McAuliffe T, Wilson J, et al.
J Interferon Cytokine Res
. 1996 Nov;
16(11):891-902.
PMID: 8938564
Fifteen patients with stage II, IIIA, and IIIB non-small cell lung cancer (NSCLC) received subcutaneous (s.c.) recombinant, glycosylated, human interferon-beta 1a (Rebif; rHuIFN-beta 1a) on each day of conventionally fractionated...